Over-expression of FSCN1 in a variety of tumours such as lung (Pelosi et al, 2003), prostate (Darnel et al, 2009), oesophageal (Zhang et al, 2006), breast (Grothey et al, 2000), colon (Jawhari et al, 2003), pancreas (Maitra et al, 2003), ovary (Lin et al, 2009b), and skin cancers (Goncharuk et al, 2002) usually correlates with high-grade, extensive invasion, distant metastasis, and poor prognosis. Here, FSCN1 is linked to neoplasm.